Gülfizar SÖZERİVARMA, RUKİYE FİLİZ KARADAĞ, Emel AYDIN, MEHMET EMİN ERDAL, Özlem İZCİAY, Hasan HERKEN, Tuba GÖKDOĞANEDGÜNLÜ

Şizofrenide DRD3 ser9gly polimorfizmlerinin bilişsel işlevlerle ilişkisi: Bir ön çalışma

Amaç: Dopamin şizofreni etiyopatogenezinde ve bilişsel işlevlerde önemli rolü olan bir nörotransmitterdir. Bu çalışma- da, şizofreni hastalarında dopamin reseptör 3 (DRD3) Ser9Gly polimorfizmi ile klinik belirtiler ve bilişsel işlevler arasın- daki ilişkinin araştırılması amaçlanmıştır. Yöntem: Çalışmaya DSM-IV tanı ölçütlerine göre şizofreni tanısı konan 40 hasta alındı. Psikotik belirtilerin şiddeti Pozitif ve Negatif Belirtileri Değerlendirme Ölçekleri ile değerlendirildi. DRD3 Ser9Gly polimorfizmleri, serin/serin (Ser/Ser), serin/glisin (Ser/Gly) ve glisin/glisin (Gly/Gly) olarak genotiplendirildi. Bilişsel işlevler için Wisconsin Kart Eşleme Testi (WKET), Stroop Testi (ST) ve Sözel Bellek Süreçleri Testi (SBST) uygulandı. Bulgular: Hastaların yaş ortalaması 37.84±12.68 yıl, eğitim yılı ortalaması 10.33±3.42 olarak saptandı. Ser/Ser genotipine sahip olan hastaların SAPS puanları Gly/Gly genotipine sahip olanlara göre yüksek bulundu. Nöro- psikolojik test aşamasını 38 hasta tamamladı. Ser/Ser genotipine sahip hastaların WKET kavramsal düzey tepki sayı- sı Ser/Gly genotipine sahip olanlara göre daha düşüktü. Hastalar, Ser/Ser genotipine sahip olanlar ve glisin alleli taşı- yanlar olarak gruplandırıldı. Ser/Ser genotipine sahip hastaların, glisin alleli taşıyanlara göre SANS puanlarının yüksek, SAPS puanlarının istatistiksel olarak anlamlılığa yakın derecede yüksek olduğu saptandı. Ser/Ser genotipine sahip olan hastaların diğerlerine göre, WKET yanlış sayısı ve perseveratif hata sayısı yüksek, doğru sayısı, tamamla- nan kategori sayısı, kavramsal düzey tepki yüzdesi ve kavramsal düzey tepki sayısı düşük bulundu. Gruplar arasında ST ve SBST puanlarında farklılık saptanmadı. Sonuçlar: Çalışmamızda, DRD3 Ser/Ser genotipine sahip hastaların glisin alleli taşıyanlara göre daha fazla psikotik belirti ve yürütücü işlev bozukluğuna sahip olduğu tespit edildi. Bu bulgular, DRD3 Ser9Gly polimorfizmlerinin psikotik belirti şiddeti ve yürütücü işlevlerle ilişkili olabileceğini göstermek- tedir. (Anadolu Psikiyatri Derg 2012; 13:184-190)

The relationship DRD3 Ser9Gly polymorphisms and cognitive functions in schizophrenia: a preliminary study

Objective: Dopamine is a neurotransmitter that plays an important role in the etiopathogenesis of schizophrenia and cognitive functions. The aim of this study was to investigate the effects of the Ser9Gly polymorphisms of dopamine D3 receptor (DRD3) on clinical features and cognitive functions in schizophrenia. Methods: The subjects were comprised of 40 outpatients with schizophrenia fulfilling the DSM-IV criteria. Psychotic symptoms were assessed with Scale for the Assessment of Positive Symptoms (SAPS) and Scale for the Assessment of Negative Symptoms (SANS). The DRD3 Ser9Gly polymorphisms were genotyped as serine/serine (Ser/Ser), serine/glycine (Ser/Gly), glycine/glycine (Gly/Gly). Neuropsychological evaluation included Wisconsin Card Sorting Test (WCST), Stroop Test (ST), and Verbal Memory Processes Test (VMPT). Results: The mean age of patients was 37.84±12.68, mean education year was 10.33±3.42. It was determined that patients with DRD3 Ser/Ser genotype had higher SAPS scores than those with Gly/Gly genotype. Thirty-eight patients completed the neuropsychological tests. The WCST conceptual response lev- els of patients with Ser/Ser genotype were lower than those of the patients with Ser/Gly genotype. The patients were grouped as Ser/Ser genotype carriers and glycine allele carriers. It was found that the patients with DRD3 Ser/Ser genotype had higher scores of SANS and SAPS (close to the level of statistical significance) in comparison to glycine allele carriers. Patients with Ser/Ser genotype had higher scores of errors and perseverative error, had lower scores of correct, number of completed categories, the percentage of conceptual level responses and number of conceptual evel responses at WCST compared to those of the other group. There was no difference between groups regarding scores of ST and VMPT. Conclusion: The patients with DRD3 Ser/Ser genotype had more psychotic symptoms and executive dysfunctions than the glycine allele carriers. These results show that DRD3 Ser9Gly polymorphism may be related with psychotic symptom severity and executive functions. (Anatolian Journal of Psychiatry 2012; 13:184- 190)

PDF

___

Mahurin RK, Velligan DI, Miller AL. Executive-frontal lobe cognitive dysfunction in schizophrenia: a symptom subtype analysis. Psychiatry Res. 1998; 79:139-149.
Aleman A, Hijman R, de Haan EH, Kahn RS. Memory impairment in schizophrenia: a meta-analysis. Am J Psychiatry. 1999; 156:358-366.
Perlstein WM, Carter CS, Noll DC, Cohen JD. Relation of prefrontal cortex dysfunction to working memory and symptoms in schizophrenia. Am J Psychiatry 2001; 158:1105-13.
Be ́chard-Evans L, Iyer S, Lepage M, Joober R, Malla A. Investigating cognitive deficits and symptomatology across pre-morbid adjustment patterns in first-episode psychosis. Psychol Med. 2010; 40: 749-759.
Leeson VC, Robbins TW, Franklin C, Harrison M, Harrison I, Ron MA et al. Dissociation of long-term verbal memory and fronto-executive impairment in first-episode psychosis. Psychol Med 2009; 39:1799-808.
Alptekin K. Şizofreni tedavisinde yeni kuşak antipsikotikler: dopamin sistemi dengeleyicileri ve aripiprazol. Klinik Psikofarmakoloji Bulteni 2008; 18 (Suppl.1): 21-26.
Bilder RM, Volavka J, Czobor P, Malhotra AK, Kennedy JL, Ni X, et al. Neurocognitive correlates of the COMT Val(158)Met polymorphism in chronic schizophrenia. Biol Psychiatry 2002; 52:701-707.
Akil M, Kolachana BS, Rothmond DA, Hyde TM, Weinberger DR, Kleinman JE. Catechol-O-methyltransferase genotype and dopamine regulation in the human brain. J Neurosci. 2003; 23:2008-2013.
Handoko HY, Nyholt DR, Hayward NK, Nertney DA, Hannah DE, Windus LC, et al. Separate and interacting effects within the catechol-O-methyltransferase (COMT) are associated with schizophrenia. Mol Psychiatry 2005; 10:589-597.
Sözeri Varma G, Karadağ F, Erdal ME, İzci Ay Ö, Levent N, Tekkanat Ç, ve ark. Katekol-O-metiltransferaz geni Val158Met polimorfizminin şizofreni hastalarındaki bilişsel işlevlere etkileri. Klinik Psikofarmakoloji Bülteni 2011; 21:24-32.
Oak JN, Oldenhof J, Van Tol Hubert HM. The dopamine D receptor: one decade of research. Eur J Pharmacol 2000; 405:303-327.
Sayın A. Dopamin reseptörleri ve sinyal iletim özellikleri. Klinik Psikiyatri Dergisi 2008; 11:125-134.
Uzbay T. Şizofreni tedavisinde yeni farmakolojik yaklaşımlar. Türk Psikiyatri Dergisi 2009; 20:175-182.
Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 1990; 13:146-151.
Scarselli M, Novi F, Schallmach E, Lin R, Baragli A, Colzi A, et al. D2/D3 dopamine receptor heterodimers exhibit unique functional properties. J Biol Chem 2001; 276:30308-30314.
Spurlock G, Williams J, McGuffin P, Aschauer HN, Lenzinger E, Fuchs K et al. European Multicentre Association study of schizophrenia: a study of the DRD2 Ser311Cys and DRD3 Ser9Gly polymorphisms. Am J Med Genet. 1998; 7:24-28.
Liao DL, Yeh YC, Chen HM, Chen H, Hong CJ, Tsai SJ. Association between the Ser9Gly polymorphism of the dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients. Neuropsychobiology 2001; 44: 95-98.
Lerer B, Segman RH, Fangerau H, Daly AK, Basile VS, Cavallaro R et al. Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology. 2002; 27:105-119.
Barlas IO, Cetin M, Erdal ME, Semiz UB, Basoglu C, Ay ME, et al. Lack of association between DRD3 gene polymorphism and response to clozapine in Turkish schizophrenia patients. Am J Med Genet B Neuropsychiatr Genet 2009; 150:56-60.
Szekeres G, Kéri S, Juhász A, Rimanóczy A, Szendi I, Czimmer C, et al. Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2004; 124:1-5.
Bombin I, Arango C, Mayoral M, Castro-Fornieles J, Gonzalez-Pinto A, Gonzalez-Gomez et al. DRD3, but not COMT or DRD2, genotype affects executive functions in healthy and first-episode psychosis adolescents. Am J Med Genet B Neuropsychiatr Genet 2008; 147:873-879.
Andreasen NC. Methods for assessing positive and negative symptoms. Mod Probl Pharmacopsychiatry 1990; 24:73-88.
Erkoç Ş, Arkonaç O, Ataklı C, Özmen E. Reliability and validity of the Turkish version of Scale for the Assessment of Positive Symptoms (SAPS). Düşünen Adam 1991; 4:20- 24.
Erkoç Ş, Arkonaç O, Ataklı C, Özmen E. Reliability and validity of the Turkish version of Scale for the Assessment of Negative Symptoms (SANS). Düşünen Adam 1991; 4:16-19.
Heaton RK, Chelune GJ, Talley JL, Kay GG, Curttis CG. Wisconsin card sorting test manual: Revised and expanded. Florida, Psycological Assesment Resources, 1993.
Karakaş S. BİLNOT Bataryası El Kitabı: Nöropsikolojik Testler için Araştırma ve Geliştirme Çalışmaları. İkinci baskı, Ankara, Eryılmaz Ofset, 2006.
Stroop JR. The basis of ligons theory. Am J Psychol 1935; 47:499-504.
Rey A. Lexamen clinique en psychologie. Paris, Presse Universitaire de France, 1964.
Öktem-Tanor O. A verbal test of memory processes: a preliminary study. Arch Neuropsychiatry 1992; 29:196-206.
Miller SA, Dykes, DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16:1215.
Hawi Z, McCabe U, Straub RE, O'Neill A, Kendler KS, Walsh D, et al. Examination of new and reported data of the DRD3/MscI polymorphism: no support for the proposed association with schizophrenia. Mol Psychiatry 1998; 3:150-155.
Malhotra AK, Goldman D, Buchanan RW, Rooney W, Clifton A, Kosmidis MH, et al. The dopamine D3 receptor (DRD3) Ser9Gly polymorphism and schizophrenia: a haplotype relative risk study and association with clozapine response. Mol Psychiatry 1998; 3:72-75.
Krebs MO, Sautel F, Bourdel MC, Sokoloff P, Schwartz JC, Olié JP, et al. Dopamine D3 receptor gene variants and substance abuse in schizophrenia. Mol Psychiatry 1998; 3:337-341.
Scharfetter J, Chaudhry HR, Hornik K, Fuchs K, Sieghart W, Kasper S, et al. Dopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic Pakastani patients. Eur Neuropsychopharmacol 1999; 10:17-20.
Tee SF, Tang PY, Loh HC. No evidence for association between DRD3 and COMT with schizophrenia in a Malay population. Genet Mol Res 2011; 10:1850-1855.
Chen CH, Liu MY, Wei FC, Koong FJ, Hwu HG, Hsiao KJ. Further evidence of no association between Ser9Gly polymorphism of dopamine D3 receptor gene and schizophrenia. Am J Med Genet 1997; 74:40-43.
Lorenzo CV, Baca-Garcia E, Hernandez MD, MartinPerez-Rodriguez MM, Saiz-Gonzalez MD, et al. No asso-
ciation between the Ser9Gly polymorphism of the dopa- mine D3 receptor gene and schizophrenia in a Spanish sample. Am J Med Genet B Neuropsychiatr Genet 2007; 144:344-346.
Utsunomiya K, Shinkai T, De Luca V, Hwang R, SakataFukunaka Y, et al. Genetic association between the dopamine D3 gene polymorphism (Ser9Gly) and schizophrenia in Japanese populations: evidence from a case-control study and meta-analysis. Neurosci Lett 2008; 444:161-165.
Fathalli F, Rouleau GA, Xiong L, Tabbane K, BenkelfatDeguzman R et al. No association between the DRD3
Ser9Gly polymorphism and schizophrenia. Schizophr2008; 98:98-104.
Sáiz PA, García-Portilla MP, Arango C, Morales B, AriasCorcoran P, et al. Genetic polymorphisms in the dopa- mine-2 receptor (DRD2), dopamine-3 receptor (DRD3), and dopamine transporter (SLC6A3) genes in schizophrenia: Data from an association study. Prog Neuropsycho pharmacol Biol Psychiatry 2010; 34:26-31.
Ma G, He Z, Fang W, Tang W, Huang K, Li Z, et al.Ser9Gly polymorphism of the dopamine D3 receptor gene and risk of schizophrenia: an association study and a large meta-analysis. Schizophr Res 2008; 101:26-35.
Lane HY, Hsu SK, Liu YC, Chang YC, Huang CH, Chang WH. Dopamine D3 receptor Ser9Gly polymorphismrisperidone response. J Clin Psychopharmacol 2005;6-11.
Rybakowski JK, Borkowska A, Czerski PM, KapelskiDmitrzak-Weglarz M, Hauser J. An association studydopamine receptors polymorphisms and the Wisconsin Card Sorting Test in schizophrenia. J Neural Transm 2005; 112:1575-1582.
Chen PS, Yang YK, Lee YS, Yeh TL, Lee IH, Chiu NT,al. Correlation between different memory systemsstriatal dopamine D2/D3 receptor density: a single photon emission computed tomography study. Psychol Med 2005; 35:197-204.
Sigala S, Missale C, Spano P. Opposite effects of dopa- mine D2 and D3 receptors on learning and memory inrat. Eur J Pharmacol 1997; 336:107-112.
Lumme V, Hirvonen MM, Ilonen T, Hirvonen J, NågrenHietala J. Cortical dopamine D2/D3 receptors and verbal memory in man. Neuroimage 2010; 51:918-922.
Özen NE, Rezaki M. Prefrontal Korteks: bellek işlevibunama ile ilişkisi. Türk Psikiyatri Dergisi 2007; 18:262- 269.